Kellokumpu-Lehtinen P, Bergh J, Salminen E, Wiklund T, Lehtinen S, Aronen P, et al. Cost-effectiveness of intensive adjuvant chemotherapy for high-risk breast cancer: Is tailored and dose-escalated chemotherapy with growth factor support (GFS) more costly and less effective than marrow-supported high-dose chemotherapy – results from a ra. AO [Internet]. 2007 Jan. 1 [cited 2026 May 17];46(2):146-52. Available from: https://medicaljournalssweden.se/actaoncologica/article/view/26218